Search research articles
Contact Us
Filters
Showing results (241-250 of 279) with videos related to
Page
of 28
Sort By:
Blood
|
July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
Blood
|
February 21, 2008
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke, Alfred Reiter, Martin Zimmermann, et al.
Leukemia
|
June 27, 2021
DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis
Linea N Toksvang, Kathrine Grell, Jacob Nersting, et al.
Hemasphere
|
September 4, 2025
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy
Gunnar Cario, Maria Grazia Valsecchi, Valentino Conter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Blood
|
August 29, 2018
Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group
Sanne Noort, Martin Zimmermann, Dirk Reinhardt, et al.
Haematologica
|
June 29, 2014
The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse
Obul R Bandapalli, Stephanie Schuessele, Joachim B Kunz, et al.
Haematologica
|
February 2, 2019
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
Carmelo Rizzari, Claudia Lanvers-Kaminsky, Maria Grazia Valsecchi, et al.
Blood
|
February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
Blood
|
February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Page
of 28
Search research articles
Search
Showing results (241-250 of 279) with videos related to
Sort By:
Page
of 28
Blood
|
July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
Blood
|
February 21, 2008
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke, Alfred Reiter, Martin Zimmermann, et al.
Leukemia
|
June 27, 2021
DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis
Linea N Toksvang, Kathrine Grell, Jacob Nersting, et al.
Hemasphere
|
September 4, 2025
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy
Gunnar Cario, Maria Grazia Valsecchi, Valentino Conter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Blood
|
August 29, 2018
Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group
Sanne Noort, Martin Zimmermann, Dirk Reinhardt, et al.
Haematologica
|
June 29, 2014
The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse
Obul R Bandapalli, Stephanie Schuessele, Joachim B Kunz, et al.
Haematologica
|
February 2, 2019
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
Carmelo Rizzari, Claudia Lanvers-Kaminsky, Maria Grazia Valsecchi, et al.
Blood
|
February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
Valentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
Blood
|
February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Page
of 28